active site / treatment of ErbB2-positive breast cancer / treatment of neoplastic disorders / segment tyrosine phosphorylation site / online version / cancer therapy / treatment of breast cancer / aspartate side chain / adenine binding site / actual site / treatment of metastatic breast cancer / treatment of ERBB1-mutant lung cancer / treatment of ErbB2-overexpressing breast cancer / treatment of lung cancer / treatment of colorectal and head and neck cancer / treatment of colorectal cancer / alignment algorithm / /
MedicalCondition
ERBB1-mutant lung cancer / Cancers / breast cancers / ErbB2-positive breast cancer / positive melanomas / cancer / NSCLC / colorectal cancer / nervous disorders / rheumatoid arthritis / ErbB2-overexpressing breast cancer / diabetes / melanomas / gastroesophageal cancers / metastatic breast cancer / lung cancer / pancreatic carcinomas / diseases / disorder / non-small cell lung cancer / drug-resistant tumors / head and neck cancer / neoplastic disorders / breast cancer / residue Regulatory spine Targeted cancer / /
MedicalTreatment
cancer therapy / /
Organization
FDA / Blue Ridge Institute for Medical Research / United States Food and Drug Administration / /
Person
R. Roskoski Jr. / D. As / John Kuriyan / Robert Roskoski Jr. / / /
Product
glycine / ErbB2 / Tyr869 / /
ProvinceOrState
North Carolina / /
Technology
drug discovery / X-ray / alignment algorithm / antibodies / directed mutagenesis / treating cancer / spectroscopy / cell signaling / ALE / Ado / drug development / apoptosis / /
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors